CPRX Q3 2023 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$103M+79.4% YoY

Gross Profit

$89M86.2% margin

Operating Income

-$37M-36.2% margin

Net Income

-$31M-30.0% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$45M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$413M

Total Liabilities

$65M

Stockholders' Equity

$349M

Cash & Equivalents

$121M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$57M	+79.4%
Gross Profit	$89M	$48M	+86.1%
Operating Income	-$37M	$25M	-248.1%
Net Income	-$31M	$23M	-235.2%

Revenue Segments

Product Revenue Net

$103M100%

License And Other Revenue

$71,0000%